TrialThe Lancet. Oncology2017

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

David Cameron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.